Eli Lilly and CoXSWX:LLY 100 Return-on-Tangible-Asset is 28.95% as of Mar. 2026, which is 81% above its 10-year median of 15.97. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,132.28 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Eli Lilly and Co ranks better than 97.31% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Eli Lilly and Co's annualizedNet Income for the quarter that ended in Mar. 2026 was CHF23,291 Mil. Eli Lilly and Co's average total tangible assets for the quarter that ended in Mar. 2026 was CHF80,442 Mil. Therefore, Eli Lilly and Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 28.95%.
The historical rank and industry rank for Eli Lilly and Co's Return-on-Tangible-Asset or its related term are showing as below:
XSWX:LLY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -0.61 Med: 15.97 Max: 26.74
Current: 26.74
During the past 13 years, Eli Lilly and Co's highest Return-on-Tangible-Asset was 26.74%. The lowest was -0.61%. And the median was 15.97%.
XSWX:LLY's Return-on-Tangible-Asset is ranked better than 97.31% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs XSWX:LLY: 26.74
Eli Lilly and Co (XSWX:LLY) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Eli Lilly and Co Return-on-Tangible-Asset Related Terms
Eli Lilly and Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LLY vs JNJ, ABBV, MRK: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 28.95% mean?
Eli Lilly and Co (XSWX:LLY) has a Return-on-Tangible-Asset of 28.95% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eli Lilly and Co and its competitors. This is 81% above median its historical median of 15.97. According to the industry distribution chart, Eli Lilly and Co ranks #27 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Eli Lilly and Co's Return-on-Tangible-Asset too high?
Eli Lilly and Co's current Return-on-Tangible-Asset of 28.95% is 81% above median its 10-year median of 15.97. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Eli Lilly and Co's value of 28.95% is 819% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #27 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Return-on-Tangible-Asset compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #27 out of 1003 companies for Return-on-Tangible-Asset. This places Eli Lilly and Co in the top 3% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Eli Lilly and Co's value of 28.95% is 819% above this benchmark. While the company's 10-year median is 15.97 vs. the industry median of 3.15, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Return-on-Tangible-Asset of 28.95% is 819% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Return-on-Tangible-Asset is 28.95%, which is 81% above median its own 10-year median of 15.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,132.28, compared to a current price of CHF970.00 — trading 14.3% below its estimated fair value. The current Return-on-Tangible-Asset is 28.95%, which is 81% above median its 10-year median of 15.97 and 819% above the Drug Manufacturers industry median of 3.15. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Return-on-Tangible-Asset is 28.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF970.00 is trading 14.3% below its estimated GF Value™ of CHF1,132.28.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Return-on-Tangible-Asset: 28.95% (81% above median its 10-year median of 15.97)
GF Value™: CHF1,132.28 vs. price of CHF970.00 (14.3% below fair value)
Industry Position: 819% above the Drug Manufacturers median (#27 of 1003)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
